← Back to Search

1% YP-P10 Ophthalmic Solution for Dry Eye Syndrome

Phase 2

Waitlist Available

Research Sponsored by Yuyu Pharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 85

Awards & highlights

Study Summary

This trial is testing whether a new eye drop is more effective and safe than a placebo eye drop for treating dry eye.

Eligible Conditions

Dry Eye Syndrome

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 85

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 85

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 85 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Ocular discomfort score of both eyes using the VAS

Total corneal fluorescein staining score of the study eye using the modified NEI scale

Secondary outcome measures

Adverse event query

Conjunctival redness

Daily compliance diary

+11 more

Trial Design

3Treatment groups

Active Control

Placebo Group

Group I: 1% YP-P10 Ophthalmic SolutionActive Control1 Intervention

Group II: 0.3% YP-P10 Ophthalmic SolutionActive Control1 Intervention

Group III: YP-P10 Placebo Ophthalmic Solution (vehicle)Placebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Yuyu Pharma, Inc.Lead Sponsor

7 Previous Clinical Trials

528 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being monitored as part of this research initiative?

"This trial requires 240 qualified participants and is being offered at two distinct sites: Cornea Consultants of Arizona in Phoenix, AZ and Andover Eye Associates in Massachusetts."

Answered by AI

What risks are posed by 0.3% YP-P10 Ophthalmic Solution to those using it?

"Since there is some existing data that supports safety, but no evidence yet for efficacy, our team have assigned a rating of 2 to 0.3% YP-P10 Ophthalmic Solution on the 1-3 scale."

Answered by AI

What is the primary purpose of this clinical research?

"Yuyu Pharma, Inc., the sponsor of this trial, lists Ocular discomfort score of both eyes using the Visual Analogue Scale (VAS) as its primary outcome measure to be observed over an 85-day period. Secondary outcomes include Daily Compliance Diary verification, Adverse Event Query and Tear Film Break-Up Time assessment for each eye."

Answered by AI

Are there any openings for participation in this clinical experiment?

"Data on clinicaltrials.gov reveals that recruitment for this medical trial is currently ongoing – the study was initially posted on June 27th 2022 and its details were last updated two weeks later, on July 15th."

Answered by AI

How many facilities are administering this research project?

"Patients can enroll in this medical research at Cornea Consultants of Arizona (Phoenix, AZ), Andover Eye Associates (Andover, MA), and Oculus Research (Garner, NC) along with 7 additional sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)

2022. "Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05467293.

All > Dry Eye